Related Experiment Video
Updated: Aug 15, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer
Alexandra Prtilo1, Fredrick S Leach, Regula Markwalder
1Urology Research Laboratory, Department of Urology, University of Bern, Inselspital, Bern, Switzerland.
The Journal of Urology
|October 12, 2005
Summary
Prostate cancer patients with low human MutS homolog 2 (hMSH2) expression showed better survival rates. hMSH2 levels correlate with Gleason score and patient outcomes, suggesting its potential as a prognostic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mismatch repair (MMR) genes correct DNA replication errors.
- Altered MMR gene expression occurs in some prostate cancers (PCs).
- hMSH2 expression levels may predict recurrence after prostatectomy.
Purpose of the Study:
- To compare hMSH2 expression and survival in organ-confined prostate cancer.
- To investigate the correlation between hMSH2 immunohistochemical staining and patient outcomes.
Main Methods:
- Prostate tissue microarray from 243 patients undergoing radical prostatectomy.
- Immunohistochemistry used to evaluate hMSH2 expression (0-4 scale).
- Low expression defined as score < 2; high expression as score ≥ 2.
Main Results:
- Higher Gleason score correlated with increased hMSH2 expression (p < 0.0002).
- Low hMSH2 expression linked to improved overall, disease-free, and biochemical disease-free survival (all p < 0.01).
- Significant differences in survival observed between low and high hMSH2 expression groups.
Conclusions:
- hMSH2 is differentially expressed in malignant prostate tissue.
- hMSH2 staining intensity correlates with Gleason score and survival outcomes.
- hMSH2 may serve as a prognostic biomarker for clinically organ-confined prostate cancer.
